Blockchain Registration Transaction Record

NeuroOne Hits Record Procedure Volume, Advances in $1B+ Pain & Brain Markets

NeuroOne reports record OneRF procedure volume & trigeminal neuralgia success. Advancing in $1B+ brain, pain & drug delivery markets with FDA clearances & Zimmer Biomet partnership. 2026 revenue guidance $10.5M+.

This news matters because NeuroOne's medical technology addresses some of the most debilitating neurological conditions affecting millions worldwide, including epilepsy, trigeminal neuralgia (often called 'the suicide disease' due to its severity), and aggressive brain cancers. Their minimally invasive approaches could revolutionize treatment paradigms by reducing hospitalizations, lowering healthcare costs, and improving patient quality of life. The company's progress in billion-dollar markets like chronic pain management and targeted drug delivery represents potential breakthroughs where current treatments often fall short. For investors, NeuroOne's growing commercial traction, strategic partnerships with industry leaders like Zimmer Biomet, and capital-efficient platform approach demonstrate a viable path to addressing massive unmet medical needs while creating shareholder value.